tranexamic acid has been researched along with Hyperpigmentation in 25 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Hyperpigmentation: Excessive pigmentation of the skin, usually as a result of increased epidermal or dermal melanin pigmentation, hypermelanosis. Hyperpigmentation can be localized or generalized. The condition may arise from exposure to light, chemicals or other substances, or from a primary metabolic imbalance.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral tranexamic acid has been used in different types of hyperpigmentation disorder, including postinflammatory hyperpigmentation treatment and prevention, lichen planus pigmentosus, ashy dermatosis, and Riehl melanosis in a dose range from 250 mg per day to 1500 mg per day for a period range from 2 weeks to 6 months with variable efficacy and a good safety profile." | 9.41 | Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review. ( Mahjoub, TT; Milibary, HH, 2023) |
| "Tranexamic acid is used for the treatment of hyperpigmentation, and the topical route is the most favorable route for its administration." | 8.31 | Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders. ( Verma, P; Yadav, KS, 2023) |
| "Our study suggests that tranexamic acid could be an effective treatment for lichen planus pigmentosus with a good safety profile." | 7.96 | [Oral tranexamic acid in the treatment of lichen planus pigmentosus: A prospective study of 20 cases]. ( Chiheb, S; Elfetoiki, FZ; Hali, F; Skalli, H; Zenjari, L, 2020) |
| " Considering the dosage and duration of treatment, an optimal protocol may be needed to induce the efficacy of this treatment to achieve the PIH-preventing effect of oral TA." | 6.76 | A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser. ( Araki, J; Doi, K; Eto, H; Higashino, T; Hirai, R; Kato, H; Kuno, S; Yoshimura, K, 2011) |
| "Post-acne hyperpigmentation is a common undesirable sequela of acne vulgaris that causes distress for many patients." | 5.62 | Tranexamic acid versus fractional carbon dioxide laser in post-acne hyperpigmentation. ( Abdel Hay, R; Elmasry, MF; Salim, H; Tawfic, SO, 2021) |
| "Oral tranexamic acid has been used in different types of hyperpigmentation disorder, including postinflammatory hyperpigmentation treatment and prevention, lichen planus pigmentosus, ashy dermatosis, and Riehl melanosis in a dose range from 250 mg per day to 1500 mg per day for a period range from 2 weeks to 6 months with variable efficacy and a good safety profile." | 5.41 | Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review. ( Mahjoub, TT; Milibary, HH, 2023) |
| "Tranexamic acid is used for the treatment of hyperpigmentation, and the topical route is the most favorable route for its administration." | 4.31 | Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders. ( Verma, P; Yadav, KS, 2023) |
| " Tranexamic acid was used as a model drug to evaluate the suitability of formulation to prevent symmetric hyperpigmentation." | 4.12 | Design and development of tranexamic acid loaded film-forming gel to alleviate melasma. ( Chevala, NT; Dsouza, JA; Kumar, L; Saini, H, 2022) |
| "Our study suggests that tranexamic acid could be an effective treatment for lichen planus pigmentosus with a good safety profile." | 3.96 | [Oral tranexamic acid in the treatment of lichen planus pigmentosus: A prospective study of 20 cases]. ( Chiheb, S; Elfetoiki, FZ; Hali, F; Skalli, H; Zenjari, L, 2020) |
| "Melasma is a hyperpigmentary disorder causing cosmetic disfigurement." | 3.30 | Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial. ( Alizadeh, M; Fatemi Naeini, F; Poostiyan, N; Shahmoradi, Z, 2023) |
| " Both treatments considered safe for MA." | 3.11 | Comparison of the efficacy and safety of intralesional injection of tranexamic acid and the topical application of Kligman combination drug in the treatment of macular amyloidosis. ( Ghassemi, M; Goodarzi, A; Kamani, SA; Roohaninasab, M; Sadeghzadeh-Bazargan, A, 2022) |
| "Oral tranexamic acid (TXA) is a relatively new treatment option for melasma." | 3.11 | A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma. ( Berger, L; Perveen, S; Rao, B; Rubin, A; Sharif, S; Waqas, N; Xiong, W, 2022) |
| "Microneedling is an alternative treatment for melasma especially by improving penetration of pharmacological agents into the skin." | 2.82 | Microneedling with cutaneous delivery of topical agents for the treatment of melasma: A systematic review. ( Brasil Dos Santos, J; da Silva E Souza Lorca, B; de Lima, GG; Faria de Freitas, ZM; Miranda Pinheiro, G; Nagem Lopes, LP; Teixeira da Silva, R, 2022) |
| " Considering the dosage and duration of treatment, an optimal protocol may be needed to induce the efficacy of this treatment to achieve the PIH-preventing effect of oral TA." | 2.76 | A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser. ( Araki, J; Doi, K; Eto, H; Higashino, T; Hirai, R; Kato, H; Kuno, S; Yoshimura, K, 2011) |
| "Melasma is an acquired melanogenesis dysfunction resulting in chronic hyperpigmentation commonly affecting the face and other frequently sun-exposed areas of the body." | 1.72 | Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio. ( Peng, L; Simpson, J; Ting, W, 2022) |
| "Post-acne hyperpigmentation is a common undesirable sequela of acne vulgaris that causes distress for many patients." | 1.62 | Tranexamic acid versus fractional carbon dioxide laser in post-acne hyperpigmentation. ( Abdel Hay, R; Elmasry, MF; Salim, H; Tawfic, SO, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 18 (72.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, CH | 1 |
| Tsai, YJ | 1 |
| Lin, KC | 1 |
| Hsieh, MH | 1 |
| Lin, HP | 1 |
| Hsu, SY | 1 |
| Tsai, HH | 1 |
| Hsieh, CH | 1 |
| Ghassemi, M | 1 |
| Roohaninasab, M | 1 |
| Kamani, SA | 1 |
| Sadeghzadeh-Bazargan, A | 1 |
| Goodarzi, A | 1 |
| Perveen, S | 1 |
| Rubin, A | 1 |
| Berger, L | 1 |
| Xiong, W | 1 |
| Waqas, N | 1 |
| Sharif, S | 1 |
| Rao, B | 1 |
| Brasil Dos Santos, J | 1 |
| Nagem Lopes, LP | 1 |
| de Lima, GG | 1 |
| Teixeira da Silva, R | 1 |
| da Silva E Souza Lorca, B | 1 |
| Miranda Pinheiro, G | 1 |
| Faria de Freitas, ZM | 1 |
| Simpson, J | 1 |
| Peng, L | 1 |
| Ting, W | 1 |
| Wang, JV | 1 |
| Lopez, A | 1 |
| Geronemus, RG | 1 |
| Chevala, NT | 1 |
| Dsouza, JA | 1 |
| Saini, H | 1 |
| Kumar, L | 1 |
| Mahjoub, TT | 1 |
| Milibary, HH | 1 |
| Poostiyan, N | 1 |
| Alizadeh, M | 1 |
| Shahmoradi, Z | 1 |
| Fatemi Naeini, F | 1 |
| Verma, P | 1 |
| Yadav, KS | 1 |
| Draelos, ZD | 1 |
| Diaz, I | 1 |
| Ali, FR | 1 |
| Al-Niaimi, F | 1 |
| da Silva Souza, ID | 1 |
| Lampe, L | 1 |
| Winn, D | 1 |
| Sayed, KS | 1 |
| Tuqan, S | 1 |
| Hilal, RF | 1 |
| Zenjari, L | 1 |
| Elfetoiki, FZ | 1 |
| Hali, F | 1 |
| Skalli, H | 1 |
| Chiheb, S | 1 |
| Ghandehari, R | 1 |
| Robati, RM | 1 |
| Niknezhad, N | 1 |
| Hajizadeh, N | 1 |
| Tehranchinia, Z | 1 |
| Elkamshoushi, AM | 1 |
| Romisy, D | 1 |
| Omar, SS | 1 |
| Tawfic, SO | 1 |
| Abdel Hay, R | 1 |
| Salim, H | 1 |
| Elmasry, MF | 1 |
| Desai, S | 1 |
| Ayres, E | 1 |
| Bak, H | 1 |
| Manco, M | 1 |
| Lynch, S | 1 |
| Raab, S | 1 |
| Du, A | 1 |
| Green, D | 1 |
| Skobowiat, C | 1 |
| Wangari-Talbot, J | 1 |
| Zheng, Q | 1 |
| Rutnin, S | 1 |
| Pruettivorawongse, D | 1 |
| Thadanipon, K | 1 |
| Vachiramon, V | 1 |
| Lee, DH | 1 |
| Oh, IY | 1 |
| Koo, KT | 1 |
| Suk, JM | 1 |
| Jung, SW | 1 |
| Park, JO | 1 |
| Kim, BJ | 1 |
| Choi, YM | 1 |
| Lee, YB | 1 |
| Park, SM | 1 |
| Kim, JW | 1 |
| Yu, DS | 1 |
| Kato, H | 1 |
| Araki, J | 1 |
| Eto, H | 1 |
| Doi, K | 1 |
| Hirai, R | 1 |
| Kuno, S | 1 |
| Higashino, T | 1 |
| Yoshimura, K | 1 |
| McDaniel, DH | 1 |
| Konishi, N | 1 |
| Kawada, A | 1 |
| Morimoto, Y | 1 |
| Watake, A | 1 |
| Matsuda, H | 1 |
| Oiso, N | 1 |
| Kawara, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tranexamic Acid Versus Fractional CO2 Laser in Post-inflammatory Hyperpigmentation in Acne Patients[NCT03765021] | 25 participants (Anticipated) | Interventional | 2018-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for tranexamic acid and Hyperpigmentation
| Article | Year |
|---|---|
Microneedling with cutaneous delivery of topical agents for the treatment of melasma: A systematic review.
Topics: Administration, Cutaneous; Adult; Combined Modality Therapy; Female; Humans; Hyperpigmentation; Male | 2022 |
Oral tranexamic acid in the treatment of hyperpigmentation disorder beyond melasma: A review.
Topics: Antifibrinolytic Agents; Humans; Hyperpigmentation; Lichen Planus; Melanosis; Tranexamic Acid; Treat | 2023 |
11 trials available for tranexamic acid and Hyperpigmentation
| Article | Year |
|---|---|
Laser-Assisted Drug Delivery of Tranexamic Acid by Picosecond Laser in Postinflammatory Hyperpigmentation: A Split-Area Double Blind Randomized Prospective Study.
Topics: Adult; Female; Humans; Hyperpigmentation; Lasers; Male; Middle Aged; Pharmaceutical Preparations; Pr | 2021 |
Comparison of the efficacy and safety of intralesional injection of tranexamic acid and the topical application of Kligman combination drug in the treatment of macular amyloidosis.
Topics: Administration, Topical; Amyloidosis, Familial; Humans; Hyperpigmentation; Injections, Intralesional | 2022 |
A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma.
Topics: Fluocinolone Acetonide; Humans; Hyperpigmentation; Melanosis; Tranexamic Acid; Treatment Outcome | 2022 |
Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor-blind split-face controlled trial.
Topics: Adult; Female; Humans; Hyperpigmentation; Male; Melanosis; Microinjections; Middle Aged; Tranexamic | 2023 |
Q-Switched Nd:YAG (532 nm) Laser Versus Intra-Dermal Tranexamic Acid for Treatment of Facial Ephelides: A Split Face, Randomized, Comparative Trial.
Topics: Female; Humans; Hyperpigmentation; Lasers, Solid-State; Melanosis; Tranexamic Acid; Treatment Outcom | 2021 |
Efficacy and safety of fractional CO
Topics: Carbon Dioxide; Humans; Hyperpigmentation; Lasers, Gas; Tranexamic Acid; Treatment Outcome | 2022 |
Oral tranexamic acid, hydroquinone 4% and low-fluence 1064 nm Q-switched Nd:YAG laser for mixed melasma: Clinical and dermoscopic evaluation.
Topics: Administration, Oral; Combined Modality Therapy; Humans; Hydroquinones; Hyperpigmentation; Lasers, S | 2022 |
Effect of a Tranexamic Acid, Kojic Acid, and Niacinamide Containing Serum on Facial Dyschromia: A Clinical Evaluation
Topics: Administration, Cutaneous; Adult; Dermatologic Agents; Facial Dermatoses; Female; Humans; Hyperpigme | 2019 |
A Prospective Randomized Controlled Study of Oral Tranexamic Acid for the Prevention of Postinflammatory Hyperpigmentation After Q-Switched 532-nm Nd:YAG Laser for Solar Lentigines.
Topics: Administration, Oral; Adolescent; Adult; Aged; Dermatologic Agents; Double-Blind Method; Drug Admini | 2019 |
Reduction in facial hyperpigmentation after treatment with a combination of topical niacinamide and tranexamic acid: a randomized, double-blind, vehicle-controlled trial.
Topics: Administration, Topical; Adult; Antifibrinolytic Agents; Delayed-Action Preparations; Dermatologic A | 2014 |
A prospective randomized controlled study of oral tranexamic acid for preventing postinflammatory hyperpigmentation after Q-switched ruby laser.
Topics: Administration, Oral; Adult; Aged; Antifibrinolytic Agents; Female; Humans; Hyperpigmentation; Infla | 2011 |
12 other studies available for tranexamic acid and Hyperpigmentation
| Article | Year |
|---|---|
Evaluation of oral tranexamic acid as a novel treatment for melasma with a high benefit-risk ratio.
Topics: Female; Humans; Hyperpigmentation; Melanosis; Menorrhagia; Odds Ratio; Quality of Life; Retrospectiv | 2022 |
Safety and Effectiveness of Low-Energy, Low-Density 1927-nm Fractional Thulium Fiber Laser With Tranexamic Acid for Postinflammatory Hyperpigmentation.
Topics: Humans; Hyperpigmentation; Lasers, Solid-State; Thulium; Tranexamic Acid | 2022 |
Design and development of tranexamic acid loaded film-forming gel to alleviate melasma.
Topics: Animals; Epidermis; Hyperpigmentation; Melanocytes; Melanosis; Mice; Polymers; Tranexamic Acid | 2022 |
Novel formulations for topical delivery of tranexamic acid: assessing the need of epidermal targeting for hyperpigmentation disorders.
Topics: Administration, Cutaneous; Humans; Hyperpigmentation; Liposomes; Skin; Tranexamic Acid | 2023 |
The clinical benefit of a multimodal topical approach to treating skin dyspigmentation.
Topics: Dermatologic Agents; Female; Humans; Hyperpigmentation; Niacinamide; Tranexamic Acid; Treatment Outc | 2023 |
Refining the management of hyperpigmentary disorders.
Topics: Dermatologists; Humans; Hyperpigmentation; Melanosis; Patient Care Management; Quality of Life; Self | 2020 |
New topical tranexamic acid derivative for the improvement of hyperpigmentation and inflammation in the sun-damaged skin.
Topics: Dermatologic Agents; Female; Humans; Hyperpigmentation; Inflammation; Quality of Life; Tranexamic Ac | 2021 |
[Oral tranexamic acid in the treatment of lichen planus pigmentosus: A prospective study of 20 cases].
Topics: Face; Female; Humans; Hyperpigmentation; Lichen Planus; Lichen Planus, Oral; Male; Middle Aged; Pros | 2020 |
Tranexamic acid versus fractional carbon dioxide laser in post-acne hyperpigmentation.
Topics: Acne Vulgaris; Cicatrix; Erythema; Humans; Hyperpigmentation; Lasers, Gas; Tranexamic Acid; Treatmen | 2021 |
Combination treatment of low-fluence Q-switched Nd:YAG laser and oral tranexamic acid for post-inflammatory hyperpigmentation due to allergic contact dermatitis to henna hair dye.
Topics: Antifibrinolytic Agents; Coloring Agents; Combined Modality Therapy; Cosmetic Techniques; Dermatitis | 2016 |
Use of oral therapy for the prevention of postinflammatory hyperpigmentation.
Topics: Administration, Oral; Antifibrinolytic Agents; Humans; Hyperpigmentation; Inflammation; Japan; Laser | 2011 |
New approach to the evaluation of skin color of pigmentary lesions using Skin Tone Color Scale.
Topics: Adolescent; Adult; Aged; Ascorbic Acid; Dermatologic Agents; Dermatology; Face; Female; Humans; Hype | 2007 |